Enhanced IL-1β secretion by tumor-associated neutrophils has also been described as a mechanism mediating drug resistance in experimental models of lung cancer [56], raising the hope that the inhibition of IL-1β signaling could also diminish the occurrence of tumor resistance incidences. Here, IL1B is linked to lung carcinoma.